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. One of the most common toxicities is ICI-associated colitis. This can be quite severe and closely resembles colitis associated with autoimmune pathophysiology including inflammatory bowel disease (IBD) 2, 3 . ICI-associated colitis is routinely treated with immunosuppressive therapy, including corticosteroids and/or agents targeting tumor-necrosis factor-α (TNF-α ), all of which have significant side effects. Recommendations regarding optimal management of ICI-induced colitis continue to evolve [4] [5] [6] [7] [8] [9] . Interestingly, recent randomized clinical studies suggest that other types of colitis, including Clostridium difficile-associated colitis and IBD, can be successfully treated by modulation of the gut microbiome with fecal microbiota transplantation (FMT) 10 Previously, we demonstrated that differential bacterial signatures comprise the gut microbiome of responders versus non-responders to ICI therapy and additionally showed that modulation of the gut microbiome of germ-free mice via FMT from patients could alter antitumor immunity and response to ICI therapy in gnotobiotic mice [11] [12] [13] . Other groups have also demonstrated differential bacterial signatures in the gut microbiome of patients who develop ICI-associated colitis [14] [15] [16] and have shown that targeting specific bacterial taxa may abrogate ICI-related toxicity in preclinical models 17 . However, approaches incorporating modulation of the microbiome to treat ICI-associated colitis have not yet been explored in patients. Herein, we document results from the first reported case series of two patients with refractory ICI-associated colitis successfully treated with FMT, and describe changes in the immune microenvironment following FMT, a potential mechanism of action through which modulation of the gut microbiome may impact ICIassociated colitis.
We sought to determine the impact of treatment with FMT from healthy donors in patients with refractory ICI-associated colitis and enrolled two patients onto this treatment protocol between June 2017 and January 2018 (CIND17-0036, CIND17-0058). Clinical courses for both patients are further detailed in Supplemental Figs. 1-3. The first patient was a 50-year-old female with high-grade metastatic urothelial carcinoma refractory to standard chemotherapy who was enrolled onto a trial of combined CTLA-4 and PD-1 blockade (NCT1928394). Two weeks after treatment initiation, she was hospitalized with CTCAE Grade ≥ 2 diarrhea/colitis. An infectious workup including PCR-based multiplex assay for common gastrointestinal pathogens was negative, and colonoscopy demonstrated severe colitis that endoscopically resembled ulcerative colitis ( Fig. 1a and Supplemental Figs. 3a and 4a). She received systemic corticosteroids, followed later by two doses of an anti-TNF-α agent (infliximab) as well as one dose of anti-integrin therapy (vedolizumab), but her symptoms persisted. She then received a single dose of FMT (50 g of donor stool) via colonoscopy. The second patient enrolled was a 78-year-old male with prostate cancer refractory to chemotherapy and hormonal therapy who received two doses of ipilimumab in the context of a clinical trial (NCT02113657). Three months after treatment initiation, he was hospitalized with fever and CTCAE Grade ≥ 2 diarrhea/colitis. Infectious etiologies were excluded and colonoscopy confirmed the diagnosis of ICIassociated colitis, although with a Crohn's colitis-like presentation ( Fig. 1d and Supplemental Figs. 3b and 4b) . His symptoms persisted despite systemic corticosteroids, infliximab, and vedolizumab. , multiple large ulcers and diffuse inflammatory exudate are present (in the distal 40 cm of the colon only, with normal appearing proximal colon) and remain despite months of treatment with steroids and biologic immunosuppressive agents (steroids + two doses infliximab + one dose vedolizumab) (row 2). Approximately 1 month after FMT (row 3), the colonic mucosa exhibits grossly normal vasculature, minimal patchy erythema, and near-complete healing of prior ulcers. Yellow arrows point to ulcerative lesions. This patient had full colonoscopic evaluations that examined every segment of the colon (ascending, transverse, descending, and sigmoid colon, and rectum). Endoscopy was performed once at each time point. Given the qualitative nature of endoscopic data collection and inability to provide true statistical analyses, we chose to include multiple other representative photos from the same colonoscopic evaluations (Supplemental Fig. 4a) . b, IHC analysis of mucosal biopsies of the colon/rectum prior to, and following, FMT. A single slide representative of the endoscopic biopsy specimen as a whole was stained for each patient for each time point. Representative slides from additional time points are included in Supplemental Fig. 5a . c, Analysis of changes in the density immune cell subsets (CD8 red squares, CD4 blue circles, FOXP3 black triangles) over time, expressed as a fold change from baseline based on total densities of cells expressing these markers (absolute densities are presented in Supplemental Fig. 6a ). Time points include time of diagnosis, prior to FMT, following steroids and biologic immunosuppression and following FMT. Date of FMT is represented by dotted vertical line and is designated day 0. These data represent the average cell density from four ROIs per sample (single slide per patient at each time point) with each ROI measuring 500 × 500 μ m 2 for a total of approximately 1 mm , multiple large ulcers and inflammatory exudate are present (throughout the entire colon) and remain after unsuccessful treatment with steroids and biologic immunosuppressive agents (steroid + two doses infliximab + four doses vedolizumab) (row 2). There is notable improvement following first FMT (row 3) but residual ulcers remain. Following second FMT (row 4), we note near-complete resolution of all ulcerative lesions. Again full endoscopic examinations were performed, once for each time point. Additional representative photographs from the colonoscopic evaluation are shown in Supplemental Fig. 4b . e, Immunohistochemical analysis of mucosal biopsies of the colon/rectum taken prior to first FMT and following first FMT. A single slide representative of the endoscopic biopsy specimen was stained for each patient for each time point. Representative slides from additional time points are included in Supplemental Fig. 5b . f, Analysis of changes in the density immune cell subsets (CD8 red squares, CD4 blue circles, FOXP3 black triangles) over time, expressed as a fold change from baseline based on total densities of cells expressing these markers (absolute densities are presented in Supplemental Fig.  6b ). These data represent the average cell density from four ROIs per sample (single slide per patient at each time point) with each ROI measuring 500 × 500 μ m 2 for a total of approximately 1 mm He received two doses of FMT. The source of all three FMT products was from a single healthy unrelated donor, collected at three different time points.
Both patients had complete resolution of clinical symptoms following treatment with FMT, with eventual return to normal solid daily bowel movements without further bleeding (Supplemental The patients' stool microbiomes were longitudinally sampled at indicated time points before and after FMT, along with samples from the FMT donor. Between 3,380 and 42,776 sequences were obtained for each sample (average 10,003). a, α -diversity, quantified by the inverse Simpson's index after rarefying to 3,000 sequences, as well as total observed OTU numbers, was evaluated for patient and FMT donor samples. b, Using principal coordinate analysis (PCoA) of unweighted UniFrac distances, microbiome samples from a are depicted in space with more similar samples located closer together. c, Bacterial 16S sequences from samples in a were classified by origin (unique to patient baseline, unique to donor, present in both patient baseline and donor, or absent in both patient baseline and donor). d, Sequences were classified by taxonomy at the Class level. e, Changes in the abundances of the top ten varying ten bacterial genera over time. Fig. 3 ). In the first patient, complete resolution occurred gradually within two weeks and she was weaned off steroids in seven days (Supplemental Fig. 3a) , while the second patient experienced partial improvement of gastrointestinal symptoms but with persistent ulcers on follow-up colonoscopy and recurrent abdominal pain. He experienced complete resolution after a second FMT treatment (Supplemental Fig. 3b ). Endoscopic evaluation demonstrated significant mucosal inflammation and ulceration in both patients near the time of diagnosis of ICI-associated colitis, without substantial improvement after systemic corticosteroids, anti-TNF, and anti-integrin agents. Following FMT, marked improvement was evident on endoscopic evaluation, with reduced inflammation and resolution of ulcerations (Fig. 1a,d and Supplemental Fig. 4 ). In the first patient, analysis of immune infiltrates in the colonic mucosa demonstrated a dense inflammatory infiltrate prior to FMT with a high density of CD8 + cytotoxic T lymphocytes and a low density of CD4 + FoxP3 + T cells (Fig. 1b,c and Supplemental Figs. 5a and 6a), consistent with findings from reports of autoimmune colitis 18, 19 . Following FMT, there was a substantial reduction in CD8 + T-cell density with a concomitant increase in CD4 + FoxP3 + (Fig. 1b ,c and Supplemental Figs. 5a and 6a), offering a potential mechanism through which FMT could abrogate ICI-associated toxicity. In the second patient, the density of all T-cell subtypes analyzed decreased following FMT, but the CD4 + T-cell population was relatively spared compared to the CD8 + T-cell population, with persistence again noted for CD4
+ and FoxP3 + cells (Fig. 1e ,f and Supplemental Figs. 5b, 6b, and 7).
Importantly, stool samples were collected from patients prior to FMT and serially following FMT to assess the diversity and composition of the microbiome before and after intervention via 16S ribosomal RNA gene sequencing (Supplemental Figs. 1 and  2 ). Results demonstrated variable pretreatment α -diversity compared to the healthy FMT donor (Fig. 2a) . There was no observable trend in α -diversity following treatment, measured by the inverse Simpson's index. Numbers of observed operational taxonomic units (OTUs), however, did consistently rise following each FMT in both patients, although in both cases they would later come back down (Fig. 2a) . Principal coordinates analyses (PCoA) of unweighted UniFrac distances demonstrated that the gut microbiome of patients became most similar to the FMT donor immediately following treatment, but in both cases later deviated away though remaining distinct compared to pre-FMT (Fig. 2b ). An evaluation of unique 16S sequences detectable in patient pre-FMT baseline samples and FMT products was used to determine probable bacterial origins in longitudinal samples, demonstrating considerable abundances of bacteria of donor origin that stably joined the patient's intestinal microbiome with each FMT procedure (Fig. 2c) .
We next assessed bacterial taxa present at time of colitis in these patients as well as compositional changes in the gut microbiome following treatment with FMT. Bacterial taxa present at time of colitis were quite disparate between the two patients, with a predominance of Clostridia and a notable absence of bacteria shown to be protective against ICI-associated colitis and IBD such as Bacteroidia 14, 16 and Verrucomicrobiae 20 , respectively, in the first patient and a predominance of Gammaproteobacteria (predominantly Escherichia) in the second patient, which is commonly seen in perturbed intestinal states 21 . Immediately following FMT in the first patient, donor FMT-derived bacteria had effectively colonized the intestinal tract, with nearly 75% of the sequences uniquely attributable to the FMT donor microbiome and a notably higher abundance of Akkermansia (Fig. 2d,e) . By week 7 after FMT, Akkermansia now only accounted for a small portion of her microbiome and there was further expansion of Clostridia, which were largely patient-derived in origin (Fig.  2d, left and 2e, left) . Of note, the patient also showed an expansion of Bifidobacterium after FMT, which recently was reported to abrogate ICI-related toxicity in a murine model 17 ( Fig. 2d , left and 2e, left). In the second patient, there was a notable increase in the abundance of Blautia and Bifidobacterium species after FMT, which have been associated with reduced intestinal inflammation (Fig. 2d , right and 2e, right) 22 . In addition to this, he had a decrease in the abundance of potentially pathogenic Escherichia and an increase in potentially beneficial Bacteroides after his first FMT (Fig. 2d, right  and 2e, right) . After his second FMT, he had a higher abundance of Escherichia and an eventual decrease in Bacteroides; however, his gastrointestinal symptoms steadily continued to improve (Fig. 2d,  right and 2e, right) .
Together, these cases provide provocative and novel evidence that modulation of the gut microbiome via FMT can be associated with significant and rapid improvement of refractory ICI-associated colitis with early insights into potential mechanisms. However, significant limitations exist with this very small cohort and additional studies are needed to assess the utility of this approach as well as to provide further mechanistic insight. Given the widespread application of ICI with expanding indications across cancer types, it is anticipated that there will be an increased incidence in ICI-associated colitis and other irAEs. Thus, further investigations building on this approach are critically needed.
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Methods
Donor selection stool bank is covered by the institutional review board HSC-SPH-15-0991 at the University of Texas School of Public Health. A single anonymous donor 23 provided the fecal stool employed in this study after appropriate screening (Supplemental Tables 1 and 2) . Donor stool preparation. Individual stool samples from the donor of ≥ 150 g were processed within 4 h of passage, diluted in 0.85% NaCl (1:10) with a total volume of 1,500 ml, mixed in a StomacherR 80 Master (Seward Laboratory System) in a sterilized bag, and then filtered through moistened five-layer sterile gauze in a funnel (both sterilized) within a biological safety cabinet. Frozen aliquots were stored at − 80 °C and used within 6 months of preparation. On the day of FMT, 250 ml of frozen product was dissolved and packaged into five 50 ml sterilized syringes. After reconstitution, the product was kept at 4 °C and used within 4 h.
Delivery of FMT.
As a standard procedure, colonoscopy was performed on the recipient at MD Anderson's Endoscopy Unit following an overnight colonic cleansing preparative regimen. Once the scope reached the cecum, 50 g/250 ml of liquid donor stool was delivered through the water channel of the scope to the cecum by preloaded syringes. Recipients rested in bed for 1 h post procedure before discharge from the endoscopy unit. Patients were instructed to resume their normal daily routines, including diet, following the FMT procedure.
Patient clinical histories. Patient 1 was a 50-year-old female with high-grade metastatic urothelial carcinoma metastatic to the lung and spine refractory to standard chemotherapy regimens. She was enrolled onto a trial of combined ipilimumab and nivolumab blockade (NCT1928394). Two weeks after treatment initiation, she was hospitalized with CTCAE (ommon terminology criteria for adverse events) Grade ≥ 2 diarrhea/colitis (bloody diarrhea) diagnosed clinically and confirmed with endoscopy after infectious etiologies were excluded. Her symptoms persisted despite standard therapies for colitis. This included 3 months of ongoing systemic corticosteroids with two doses of an anti-TNF-α agent (infliximab) during a prolonged hospitalization. Cytomegalovirus immunohistochemistry appeared positive on histology obtained at subsequent endoscopy; she was successfully treated with valcyclovir with resolution on followup endoscopic biopsy. As third-line therapy, one dose of anti-integrin antibody (vedolizumab) was given without further improvement. As compassionate treatment (CIND17-0036, IRB PA18-0372), she received a single dose of FMT (50 g of donor stool) via colonoscopy. The patient improved clinically. However, she eventually succumbed to progression of her primary cancer 3 months after FMT.
Patient 2 was a 78-year-old male with prostate cancer metastatic to bone refractory to chemotherapy and hormonal therapy, who received two doses of ipilimumab in the context of a clinical trial (NCT02113657). Three months after treatment initiation, he was hospitalized with fever and CTCAE Grade ≥ 2 diarrhea/colitis (diarrhea, rectal bleeding, and abdominal pain) diagnosed clinically and confirmed with endoscopy after infectious etiologies were excluded. He exhibited incomplete clinical, endoscopic, and histological improvement on standard therapies for colitis including a total of 5 months of immunosuppressive agents (systemic corticosteroids, two doses of infliximab, and four doses of vedolizumab). As compassionate treatment (CIND17-0058, IRB PA18-0372), he received FMT treatment (also 50 g of donor stool via colonoscopy), which improved his symptoms in the short term; however, multiple colonic ulcerations persisted with residual abdominal pain. He received a second dose of FMT (50 g of donor stool via colonoscopy) 2 months later under the same CIND17-0058. He has remained asymptomatic for 7 months thus far, although he has since received additional cancer treatments.
Methods for microbiome analysis. Microbiome analysis was performed on the patient samples collected pre-FMT and on days 10 and 53 after FMT, and on samples collected from the FMT donor. Genomic bacterial DNA was extracted from fecal samples using the QIAamp DNA Stool kit (Qiagen), with the addition of a bead-beating lysis step. Genomic 16S ribosomal-RNA V4 variable regions were amplified and sequenced on the Illumina MiSeq platform as previously described 24 . Between 3,380 and 42,776 sequences were obtained for each sample (average 10,003).
VSEARCH was used for analyzing nucleotide sequences 25 . Paired-end reads were merged, de-replicated, and sorted by length and size. Sequences were then error-corrected and chimera-filtered using the UNOISE algorithm (https:// www.biorxiv.org/content/early/2016/10/15/081257) to generate a preliminary list of OTUs. Both OTUs and presumed chimeras were assigned taxonomy in QIIME 26 using the Mothur method 27 with the Silva database version 128 (http:// databasecommons.org/database.jsp?db_id= 238). Additionally, sequences rejected by the UNOISE algorithm that matched a database entry with a perfect score were restored to generate the final list of OTUs. An OTU table was generated using VSEARCH, and UniFrac 28 distances between samples were determined with QIIME. For assessment of the inverse Simpson's diversity score, sample sequences were first rarefied at a number below the sample with the least number of sequences (3,000) using QIIME. In addition, principal coordinate analysis (PCoA) was used to illustrate the unweighted UniFrac distance between study patients and donor samples in two dimensions PC1 and PC2 to construct an orthogonal coordinate that displays the most variation between samples.
Methods for immunohistochemistry. Sections (4 μ m thickness) were prepared from formalin-fixed paraffin-embedded gut tissues. Slides were then stained using a Leica Bond RX automated slide stainer (Leica Biosystems) for CD3 (1:100, Dako), CD8 (1:100, Thermo Scientific), and FoxP3 (1:50, BioLegend), and counter-stained with hematoxylin. Stained slides were then scanned using an automated Aperio Slide Scanner (Leica), and the density of the immune infiltrate was quantified in tumor regions using a modified version of the default 'Nuclear v9' algorithm and expressed as positive counts per mm 2 Methods for multiplex immunofluorescence assay and multispectral analysis. For multiplexed staining, we followed the Opal protocol staining method 29 for the following markers: CD4 (1:25, CM153BK, Biocare) with subsequent visualization accomplished using fluoresceinAF-647; FoxP3 with visualization using AF-488 (1:50); CD8 (1:200, M7103, Dako) with visualization using AF-594 (1:50); and Granzyme B (1:100, PA0291, Leica Microsystems) with visualization using AF-555 (1:50). Nuclei were subsequently visualized with DAPI (1:2,000). All of the sections were cover-slipped using Vectashield Hardset 895 mounting media.
A detailed methodology for multispectral analysis is described previously 29 . Each of the individually stained sections (CD4/AF-647, CD8/AF-594, FoxP3 / AF-488, GrB /AF-555, and DAPI) were utilized to establish the spectral library of fluorophores required for multispectral analysis. The slides were scanned using the Vectra slide scanner (PerkinElmer) under fluorescent conditions. For each marker, the mean fluorescent intensity per case was then determined as a base point from which positivity calls could be established as a positivity threshold.
Methods of stool analysis for infectious agents.
Real-time PCR methodologies were performed to detect the presence of nucleic acid from the following 22 pathogens: Adenovirus F 40/41, Astrovirus, C. difficile, Campylobacter, Cryptosporidium, Cyclospora cayetanensis, Escherichia coli O157, Enteroaggregative E. coli, Enteroinvasive E. coli, Entamoeba histolytica, Enteropathogenic E. coli, Enterotoxigenic E. coli, Giardia lamblia, Norovirus GI/GII, Plesiomonas shigelloides, Rotavirus A, Salmonella, Sapovirus (I, II, IV, and V), Shiga toxin-producing E. coli, Vibrio, Vibrio cholera, Yersinia enterocolitica. Positive results were confirmed with either culture for most agents or ELISA for C. difficile.
Methods for endoscopic scoring for ICI-associated colitis. Both patients had full colonoscopic evaluations that examined every segment of the colon (ascending, transverse, descending, and sigmoid colon, and rectum). Given the qualitative nature of endoscopic data collection and an inability to provide true statistical analyses, other multiple representative photographs from the same colonoscopic evaluations were included.
An endoscopic severity score specific to ICI-associated colitis that incorporates the presence of erythema and ulcerations as well as the number and depth of mucosal ulcerations 30 was utilized. The endoscopy score consists of five characteristics with one point awarded for each of the following: (a) erythema and erosions; (b) any ulcer; (c) more than two ulcers in number; (d) ulcers larger than 1 cm surface area; and (e) ulcers deeper than 2 mm.
Statistical treatment of data and analyses. For qualitative data including endoscopy, we have included multiple representative photographs as discussed above. For the IHC, we chose a single slide from each patient for each time point to stain but have included multiple time points per patient. Stained slides were then scanned using an automated Aperio Slide Scanner (Leica), and the density of the immune infiltrate was quantified in tumor regions using a modified version of the default 'Nuclear v9' algorithm and expressed as positive counts per mm The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
nature research | reporting summary
April 2018
Data Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
Patient-related data not included in the paper were generated as part of clinical trials and may be subject to patient confidentiality. Any data and materials that can be shared will be released via a Material Transfer Agreement. Sequence data has been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS00001003217.
Field-specific reporting
Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection. Obtaining unique materials Patient-related data not included in the paper were generated as part of clinical trials and may be subject to patient confidentiality. Any data and materials that can be shared will be released via a Material Transfer Agreement.
